Article PDF
Avoid common mistakes on your manuscript.
References
Kontoghiorghes GJ. New orally active iron chelators.Lancet 1985; 1: 817.
Bartlett AN, Hoffbrand AV, Kontoghiorghes GJ. Long-term trial with the oral iron chelator 1,2-dimethyl 3-hydroxypyrid-4-one (L1). II Clinical Observations.Br J Haematology 1990; 76: 301–304.
Olivieri NF, G, Koran C, St Louis P et al. Studies of the oral chelator 1,2-dimethyl-3-hydroxypyrid-4-one in thalassemia patients.Semin Hematol 1990; 27: 101–104.
Toendury P, Kontoghiorghes GJ, Ridolfi-Luthy A et al. L1 (1,2-dimethyl-3-hydroxypyrid-4-one) for iron chelation in patients with beta-oral major.Br J Haematol 1990; 76: 550–553.
Agarwal MB, Viswanathan C, Ramananthan J et al. Oral iron chelation with L1 (letter).Lancet 1990; 335: 601.
Agarwal MB, Gupta SS, Vasandani D. Efficacy and safely of 1,2-dimethyl-3-hydroxypyrid-4-one (L1) as an oral iron chelator in patients of beta thalassemia major with iron overload.Journal Assoc Phys of India 1991; 39: 669–672.
Agarwal MB, Gupta SS, Vishwanathan C et al. Long term assessment of efficacy and safely of L1. an oral iron chelator, in transfusion dependent thalassemia India trial.Br J Haematol 1992; 82: 460–466.
Kontoghiorghes GJ. L1. 1,2-dimethyl-3-hydroxypyrid-4-one.Drugs of the Future 1988; 13: 413–415.
Kontoghiorghes GJ, Aldouri MA, Hoffbrand AV et al. Effective chelation of iron in beta thalassemia with the oral chelator 1, 2-dimethyl-3-hydroxyphrid-4-one.Br Med J 1987; 295: 1509–1512.
Mehta J, Singhal S, Revankar R et al. Fatal systemic lupus erythematosus in patient taking oral iron chelator L1 (letter).Lancet 1991; 337: 298.
Hoffbrand AV, Bartlett AN, Veys PA et al. Agranulocytosis and thrombocytopenia in a patient with Blackfan-Diamond anaemia during oral chelator trial (letter).Lancet 1989; 2: 457.
Kontoghiorghes GJ et al. Safety of oral iron chelator L1.Lancet 1989; 2: 457.
Kontoghiorghes GJ, Nasseri-Sina P, Goddard JG et al. Safety of oral iron chelator L1 (letter).Lancet 1989; 2: 4578.
Kontoghiorghes GJ. Advances in oral iron chelation in man: A review.Int J Hematol 1992; 55: 27–38.
Kontoghiorghes GJ. Updated report on the worldwide oral iron chelation therapy with L1-deferiprone and ketohydroxypyridone (abstract).5th Int Conf on Thalassemia and Haemoglobinopthies held at Cyprus, 1993; pp. 111.
Agarwal MB, Gupta SS, Vishwanathan C et al. Long term efficacy and toxicity of L1-oral iron chelation in transfusion dependent thalassemics over the last three years (1989–92) (abstract):5th Int Conf on Thalassemia and Haemoglobinopathies held at Cyprus. 1993; pp. 192.
Agarwal MB.Living with Thalassemia. Bombay: Bhalani Book Dept, 1986.
Grady RW, Graziano JH, White GP et al. The development of new iron chelating drugs (ii).Journal of Pharmacology and Experimental Therapeutics 1978; 205: 757–765.
Olivieri NF, Koren G, Klein J et al. Oral iron chelation with 1,2-dimethyl-3-hydroxypyride-4-one (L1) in thalassemia major (TM): pharmacokinetics, safety and iron excretion.Blood Suppl 1990; 76: 277.
Hider RC, Singh S, Porter JB et al. The development of hydroxypyridin-4-ones as orally active iron chelators.Ann NY Acad Sci 1990; 612: 327–338.
Kontoghiorghes GJ. The study of iron mobilization from transferrin using alpha-ketohydroxy heteroaromatic chelatores.Biochim Biophys Acta 1986; 869: 141–146.
Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV et al. Long term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) I. Iron chelation and metabolic studies.Br J Haematol 1990; 76: 295–300.
Kontoghiorghes GJ, Aldouri MA, Sheppard L et al. 1,2, dimethyl-3-hydroxypyrid-4-one, an orally active chelator for treatment of iron overload.Lancet 1987; 1: 1294–1295.
Kontoghiorghes GJ, Goddard JG, Bartlett AN et al. Pharmacokinetic studies in humans with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one.Clin Pharmacol Ther 1990; 48: 255–261.
Matsui D, Klein J, Hermann C et al. Relationship between the pharmacokinetics and iron excretion pharmacodynamics of the new oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one in patients with thalassemia.Clin Pharmacol Ther 1991; 50: 294–298.
Mehta J, Singhal S, Chablani A et al. L1-induced systemic lupus erythematosus.Indian J Hematol Blood Transf 1991; 9: 33–37.
Olivieri NF, Koren G, Freedman MH et al. Rarity of systemic lupus erythematosus in patients taking L1.Lancet 1991; 337: 924.
Agarwal MB, Vishwanathan C, Gupta SS et al. Antinuclear antibody positivity in multi-transfused thalassemia major.Indian Pediatr 1992; 29: 607–610.
Editorial. Oral iron chelators.Lancet 1989; 1: 1016–1017.
Kontoghiorghes GJ, Bartlett AN, Hoffbrand AV. Prospects for effective oral iron chelation therapy in man with 1,2-dimethyl-3-hydroxypyrid-4-one and other alphaketohydroxypyridines. In:Advances and Controversies in Thalassemia Bone Marrow Transplantation and Other Approaches. New York: Alan R. Liss Inc. 1989; 107–114.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Agarwal, M.B. Oral iron chelation: A review with special emphasis on Indian work on deferiprone (L1). Indian J Pediatr 60, 509–516 (1993). https://doi.org/10.1007/BF02751427
Issue Date:
DOI: https://doi.org/10.1007/BF02751427